300149 睿智医药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-4.401-48.47716.827-18.3166.549
总资产报酬率 ROA (%)-2.686-29.3729.037-9.6473.918
投入资产回报率 ROIC (%)-3.024-32.93910.070-10.7354.396

边际利润分析
销售毛利率 (%)19.22525.93525.42331.69038.315
营业利润率 (%)-9.263-82.25556.350-21.02113.460
息税前利润/营业总收入 (%)-8.202-81.32255.826-16.48316.977
净利润/营业总收入 (%)-8.598-80.54927.320-23.78310.396

收益指标分析
经营活动净收益/利润总额(%)83.0726.392-11.3152.37778.224
价值变动净收益/利润总额(%)-10.8950.098190.871-3.06148.711
营业外收支净额/利润总额(%)0.7170.362-2.5751.559-3.061

偿债能力分析
流动比率 (X)1.7971.7041.7490.6941.168
速动比率 (X)1.7671.6391.6910.6251.098
资产负债率 (%)35.56339.98837.76252.83940.499
带息债务/全部投入资本 (%)8.88210.32915.54431.88731.884
股东权益/带息债务 (%)802.877643.036443.387162.182206.044
股东权益/负债合计 (%)178.042147.585163.12188.150145.454
利息保障倍数 (X)-7.271-66.00862.684-3.3844.335

营运能力分析
应收账款周转天数 (天)87.71695.71891.81476.61796.373
存货周转天数 (天)8.87715.09420.31019.26724.163